Skip to main content

Table 3 Secondary endpoints

From: Asthma rehabilitation at high vs. low altitude: randomized parallel-group trial

 

Low altitude

High altitude

Between group difference of changes from BL to 3 weeks

Between group difference of changes from BL to 3 months

 

Baseline

End of rehabilitation

(3 weeks)

Follow-up

(3 months)

Baseline

End of rehabilitation

(3 weeks)

Follow-up

(3 months)

FEV1, %pred.

61 (42;77)

96 (54;80)*

71 (58;83)*

64 (59;71)

78 (67;83)***

72 (58;85)*

3.6 (−4.9 to 10.9)

1.7 (-7.3 to 9.6)

FVC, %pred.

83 (63;93)

87 (79;96)*

87 (77;94)

82 (74;92)

91 (83;98)**

84 (78;95)

1.5 (−5.5 to 10.2)

−.45 (-7.0 to 6.1)

FEV1/ FVC, pre

.63 (.52;.69)

.63 (.53;.70)

.67 (.54;.70)*

.67 (.59;.71)

.70 (.63;.75)***

.69 (.6;.75)**

.01 (−.03 to .05)

.01 (−.04 to .06)

6MWD, m

490 (452;510)

521 (493;549)***

504 (486;536)*

536 (491;571)

571 (522;624)**

570 (517;607)

−2 (-24 to 22)

4 (-26 to 31)

STS, repetitions

21 (19;24)

24 (21;26)**

25 (22;28)**

25 (23;28)

36 (30;40)***

30 (27;39)***

7 (4 to 11)

4 (0 to 7)

FeNO, ppb

37 (25;58)

19 (36;51)

51 (35;76)

27 (23;52)**

−18 (−36 to 0)

 

Hemoglobin, g/l

139 (131;150)

139 (125;145)

 

142 (127;158)

145 (138;166)

 

7 (4 to 11)

 

EOS, 10^9/l

.39 (.28;.63)

.31 (.18;.57)

 

.38 (.28;.57)

.26 (.18;.45)

 

−.05 (−.16 to .04)

 

EOS, %

6.3 (5.0;9.3)

5.4 (2.7;7.1)*

6.2 (5.1;8.6)

3.9 (2.4;6.5)***

−1.1 (−2.6 to 0.5)

 
  1. Note: Data are given as median (quartiles) and median difference (confidence interval)
  2. Abbreviations: FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, 6MWD 6 min walking distance, STS Sit-to-stand, FeNO exhaled nitric oxid, EOS blood eosinophils
  3. *: p < 0.05; **: p < 0.01; ***: p < 0.001 tested with Wilcoxon test for paired samples (baseline vs. 3 week follow up and baseline vs. 3 months follow up); bold: significant between group differences